Psychosomatic features of anxiety and depressive disorders
V. A. Verbenko, A. A. Dvirsky, A. A. Soldatenko · 2025 · Vrach. 2025;36(2):5–12.
Study findings
The authors report improvement in anxiety-related and somatic symptoms during Selank treatment. The accessible publisher abstract does not quantify a controlled treatment effect.
- Population and setting
- Patients with anxiety/depressive and somatic symptoms; original full-text methods await retrieval
- Evidence type
- Uncontrolled human report
- Source language
- Russian; English abstract
- Title source
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
Study limitations
- Publisher abstract lacks sufficient allocation, comparator and numerical outcome detail for a causal conclusion.
- Full PDF retrieval was unsuccessful; search-indexed methods fragments are not treated as a full-text review.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Abstract-level record
Source access and review scope
Publisher metadata and abstract checked; full paper not retrieved.
Recorded source-check date: 2026-10-08. This date does not imply a completed systematic review.
Citation and original source
Original source: V. A. Verbenko, A. A. Dvirsky, A. A. Soldatenko. Psychosomatic features of anxiety and depressive disorders Vrach. 2025;36(2):5–12. 2025.
Molekul research summary: https://molekul.io/research/refresh-selank-2025. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry